Earnings Estimate Revisions - Alcon Inc (ALC) is seeing favorable earnings estimate revisions, which is a precursor to a potential earnings beat [1] - The Most Accurate Estimate for the current quarter is 74 cents per share, compared to the Zacks Consensus Estimate of 72 cents per share [1] - This results in a Zacks Earnings ESP of +2.57% for ALC heading into earnings season [1] Importance of Positive Earnings ESP - A positive Zacks Earnings ESP has historically been powerful in producing positive surprises and outperforming the market [2] - Stocks with a positive Earnings ESP and a Zacks Rank 3 (Hold) or better show a positive surprise nearly 70% of the time [2] - These stocks have returned over 28% on average in annual returns [2] Alcon's Position - ALC has a Zacks Rank 2 (Buy) and a positive Earnings ESP, making it a potential candidate for consideration ahead of earnings [2] - Recent earnings estimate revisions suggest positive prospects for Alcon and a potential earnings beat in the upcoming report [2]

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highli ...

Key PointsSTAAR Surgical is the leading maker of implantable ocular lenses (IOL) used for cataract surgery.Its EVO ICL sales hit the highest levels in the United States in Q1 2024 since its FDA approval in March 2022.With over 90% of people over 65 years of age developing cataracts, STAAR Surgical has a long runway for growth from the aging population.5 stocks we like better than STAAR SurgicalSTAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natur ...

Alcon (ALC) is likely to grow in the coming quarters, backed by the flourishing Surgical business with its diversified portfolio and innovative technologies. Strength in the Vision Care business will further fuel growth. Strong, stable solvency also appears encouraging. Meanwhile, headwinds, such as macroeconomic impacts and the fiercely competitive industry, remain concerns for Alcon’s operations.  In the past year, this Zacks Rank #3 (Hold) stock has increased 17.7% compared with the 9.7% rise of the indu ...

Alcon’s (ALC) AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have recently surpassed more than one million implants worldwide. The company’s revolutionary presbyopia-correcting intraocular lens (PCIOL) option has expanded the patient candidacy pool by addressing the diverse vision needs of patients who desire less dependency on glasses post-surgery and low visual disturbances.The recent development will strongly boost the company’s Surgical business, which offe ...

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patient ...

Alcon, Inc. (NYSE:ALC) Q4 2023 Earnings Conference Call February 28, 2024 5:30 PM ET Company Participants Daniel Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Ryan Zimmerman - BTIG Susannah Ludwig - Bernstein Anthony Petrone - Mizuho Group David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Brett Fishbin - KeyBanc Capital Markets Tom Stephan - Stife ...

Alcon, Inc. (ALC) delivered core earnings per share (EPS) of 70 cents in the fourth quarter of 2023, up 66.7% from the year-ago quarter’s figure (up 78% at the constant exchange rate or CER). The figure topped the Zacks Consensus Estimate by 2.9%. Alcon’s “core” results are based on non-IFRS (International Financial Reporting Standards) measures.In the fourth quarter, the company’s diluted EPS was 86 cents compared to a loss of 20 cents per share in the prior-year quarter.For the full year, the core EPS was ...

For the quarter ended December 2023, Alcon (ALC) reported revenue of $2.33 billion, up 8.2% over the same period last year. EPS came in at $0.70, compared to $0.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of -0.22%. The company delivered an EPS surprise of +2.94%, with the consensus EPS estimate being $0.68.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they com ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 10% on a constant currency basis(1), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.86 and core diluted earnings per share(2) of $0.70 in the fourth quarter of 2023. David J. Endicott, Alco ...